Alzheimer's Disease -- Diagnosis, Treatment, and Long-Term Care
Alzheimer's disease is the most common cause of dementia worldwide. The diagnosis is no longer a description of inevitable decline -- it is the beginning of a long-term care framework that includes pharmacological treatment, psychiatric symptom management, family support, and quality of life optimization throughout the disease course.
What Is Alzheimer's Disease?
Alzheimer's disease is a progressive neurodegenerative disorder and the most common cause of dementia, accounting for approximately 60-80% of dementia cases. The disease is characterized neuropathologically by accumulation of amyloid plaques and tau tangles in the brain, with progressive neuronal loss and brain atrophy. Clinically, it manifests as gradual decline in memory and other cognitive functions, eventually affecting the capacity to carry out daily activities.
The DSM-5 framework distinguishes Major Neurocognitive Disorder due to Alzheimer's Disease (the term used for what is colloquially called "Alzheimer's dementia") from Mild Neurocognitive Disorder due to Alzheimer's Disease (earlier-stage cognitive impairment without full dementia). The diagnostic criteria emphasize: insidious onset and gradual progression, clear evidence of decline in at least one cognitive domain (typically memory in early stages), no evidence of mixed etiology, and exclusion of other causes that could explain the symptoms.
Approximately 6.7 million Americans have Alzheimer's disease as of 2023, with prevalence rising with age. After age 65, prevalence doubles approximately every 5 years -- affecting 5% of people aged 65-74, 13% aged 75-84, and 33% aged 85 and older. The disease is more common in women than men, in part because women live longer but also because of biological factors. Hispanic/Latino populations have approximately 1.5 times the risk compared to non-Hispanic white populations, with significant implications for the Tijuana-San Diego cross-border community.
The Stages of Alzheimer's Disease
Preclinical Stage
Brain changes (amyloid accumulation, tau pathology) are occurring but no clinical symptoms are yet apparent. This stage can last 10-20 years before symptom onset. Currently identifiable through biomarkers (PET imaging, cerebrospinal fluid markers, blood-based tests) in research settings; emerging into clinical use as treatments become available that may slow progression at this stage.
Mild Cognitive Impairment (MCI)
Subtle cognitive changes that are noticeable but do not yet substantially interfere with daily functioning. Memory problems that family members notice. Difficulty finding words. Slight changes in problem-solving. Approximately 10-15% of patients with MCI progress to Alzheimer's dementia each year, though not all do. This is the stage where intervention -- both pharmacological and lifestyle -- may have the greatest impact on slowing progression.
Mild Alzheimer's (Early-Stage)
Diagnosable dementia with preserved ability to perform basic activities of daily living, often with assistance for more complex tasks. Memory loss becomes more obvious. Difficulty managing finances, medications, complex household tasks. Increased word-finding problems. Some personality and mood changes may emerge. This stage typically lasts 2-4 years.
Moderate Alzheimer's (Mid-Stage)
Substantial cognitive impairment affecting most daily activities. Need for assistance with grooming, dressing, eating. Significant memory loss including remote memories. Sleep disturbance, sundowning, wandering. Behavioral and psychological symptoms often most prominent at this stage -- agitation, paranoia, hallucinations, mood changes. This stage typically lasts 2-10 years and is often the most demanding for caregivers.
Severe Alzheimer's (Late-Stage)
Complete dependence for activities of daily living. Loss of ability to communicate meaningfully. Limited mobility. Loss of swallowing function. Eventual death typically from complications -- pneumonia, infections, complications of immobility. Focus shifts to comfort, dignity, and palliative care. This stage typically lasts 1-3 years.
Variability of Progression
The above stages are approximations -- individual progression varies substantially. Some patients progress rapidly through stages; others remain in early stages for many years. Younger-onset Alzheimer's (before age 65) typically progresses more rapidly than later-onset. Comorbid conditions, vascular factors, level of cognitive reserve, and environmental factors all affect progression rate. The diagnosis describes the condition, not the precise timeline.
The Psychiatric Dimension of Alzheimer's Care
Alzheimer's disease is often considered a neurological rather than psychiatric condition -- and the diagnostic evaluation and disease-modifying treatment do involve neurology and neuropsychology centrally. But the psychiatric dimension is substantial throughout the disease course, and access to psychiatric care often determines quality of life for both patients and caregivers.
Behavioral and Psychological Symptoms of Dementia (BPSD): Approximately 90% of patients with Alzheimer's disease develop behavioral or psychological symptoms during the course of illness. These include agitation, aggression, depression, anxiety, psychosis (hallucinations, delusions), sleep disturbance, apathy, wandering, repetitive behaviors, and sundowning. BPSD often produce more distress for patients and caregivers than the cognitive symptoms themselves and are the primary driver of caregiver burnout, institutional placement, and overall care needs.
Mood Disorders: Depression occurs in approximately 30-40% of patients with Alzheimer's disease, often at higher rates in earlier stages when insight into the diagnosis is preserved. Recognition is important because depression worsens cognitive symptoms, reduces functioning, and responds to treatment. The clinical picture can be challenging because depression in Alzheimer's may present atypically -- as apathy or behavioral changes rather than typical depressive symptoms.
Anxiety: Common throughout the disease course, often driven by recognition of cognitive losses, fear of the future, and disorientation in unfamiliar environments. May worsen behavioral symptoms and reduce participation in care activities.
Psychotic Symptoms: Hallucinations (often visual) and delusions (frequently persecutory or involving misidentification of family members) occur in approximately 30-50% of patients during the disease course. These symptoms are often distressing for patients and frightening for families, and require careful management balancing symptom control against medication side effects.
Caregiver Burden and Family Impact: Alzheimer's disease is not only a patient illness -- it profoundly affects the family system. Caregiver depression, anxiety, exhaustion, and complicated grief are common and themselves require attention. Family-centered care that recognizes and addresses caregiver needs improves outcomes for both patients and their families.
The psychiatrist's role in Alzheimer's care: While neurologists typically take the lead in disease-specific treatment (including newer disease-modifying agents like aducanumab and lecanemab), psychiatrists play essential roles in managing behavioral and psychological symptoms, treating co-occurring mood and anxiety disorders, supporting caregivers, and addressing the complex psychiatric dimensions of the disease course. Coordination between specialties provides the most comprehensive care.
Treatment at Our Practice
Comprehensive Alzheimer's care combines disease-modifying treatment (when applicable), symptomatic medication, psychiatric symptom management, non-pharmacological interventions, and caregiver support.
Cognitive Symptom Treatment: Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine remain the foundation of symptomatic cognitive treatment. These medications do not modify disease progression but provide modest symptomatic benefit and may delay decline by months to years for some patients. Newer disease-modifying agents targeting amyloid (aducanumab, lecanemab) are available in some contexts but require specific clinical criteria, infusion infrastructure, and monitoring for side effects -- typically managed by specialized neurology or memory clinics rather than general psychiatry.
Behavioral and Psychological Symptom Management: First-line approach is non-pharmacological: environmental modifications, structured routines, addressing unmet needs (pain, hunger, social), validation rather than reality orientation in late stages, and caregiver education on management techniques. When medication is needed: SSRIs for depression and some BPSD; trazodone or melatonin for sleep; very cautious use of antipsychotics (with full informed consent about risks) only when symptoms are severe and non-pharmacological approaches have failed. Long-term antipsychotic use in dementia carries significant risks including increased mortality.
Treatment of Co-occurring Conditions: Active management of depression, anxiety, sleep disorders, and pain -- all of which can worsen cognitive symptoms and quality of life. Management of medical comorbidities (cardiovascular disease, diabetes, thyroid dysfunction) that affect cognitive function.
Caregiver Support: Active attention to caregiver wellbeing, education about disease progression, planning for changing care needs, connection to support groups and respite resources, and recognition that effective patient care requires sustainable caregiver capacity.
Advance Care Planning: Early-stage discussions about preferences for future care -- including advance directives, healthcare proxy designation, financial planning, and discussions about goals of care for late-stage illness. These conversations are easier and more meaningful when conducted while the patient can participate.
Follow-up visits are $95 USD and can be conducted via telepsychiatry for established patients when clinically appropriate and where legally permitted.
The Diagnosis Is the Beginning of a Long-Term Care Plan, Not the End of Hope.
Comprehensive Alzheimer's care addresses cognitive symptoms, behavioral symptoms, mood, caregiver support, and quality of life throughout the disease course. A careful evaluation establishes the framework.
Alzheimer's Care for California Residents
The Hispanic/Latino population of Southern California has elevated Alzheimer's disease prevalence and faces particular barriers to specialty care -- bilingual psychiatric services experienced in dementia care are limited, costs of comprehensive care add up substantially over the years-long disease course, and family caregivers often need support that the U.S. system inadequately provides. Cross-border care can offer accessible psychiatric support throughout the disease course, complementing rather than replacing specialty neurology when needed for disease-modifying treatment.
At New City Medical Plaza, Paseo del Centenario 9580, Piso 25, Zona Urbana Rio Tijuana -- approximately 20 minutes from the San Ysidro border crossing. We accept cash, credit cards, Zelle, and Venmo.
Frequently Asked Questions
My mother is becoming forgetful but seems otherwise fine. Should we wait, or should she be evaluated now?
My father with Alzheimer's has become aggressive and accuses my mother of cheating. How is this managed?
I am caring for my husband with Alzheimer's and feel like I am losing myself. Is there help for me?
Psychiatrist trained at UNAM and Hospital Psiquiatrico Fray Bernardino Alvarez. Certified by the Consejo Mexicano de Psiquiatria. Alzheimer's care is fundamentally long-term -- the relationship with patient and family extends over years, with care needs evolving as the disease progresses. The psychiatric dimension is substantial throughout: behavioral and psychological symptoms, mood disorders, caregiver support, and quality of life optimization. The work involves both the patient and the broader family system, with attention to what each needs at each stage of the disease course.
Scientific References
1. American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text rev.). American Psychiatric Publishing.
2. Knopman, D. S., et al. (2021). Alzheimer disease. Nature Reviews Disease Primers, 7(1), 33.
3. Alzheimer's Association. (2024). 2024 Alzheimer's Disease Facts and Figures. Retrieved from https://www.alz.org/
The Diagnosis Begins the Long-Term Care Plan. The Care Plan Matters.
Comprehensive Alzheimer's care optimizes quality of life for patient and family throughout the disease course. A careful evaluation establishes the framework.